"Fusion Proteins, bcr-abl" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
Translation products of a fusion gene derived from CHROMOSOMAL TRANSLOCATION of C-ABL GENES to the genetic locus of the breakpoint cluster region gene on chromosome 22. Several different variants of the bcr-abl fusion proteins occur depending upon the precise location of the chromosomal breakpoint. These variants can be associated with distinct subtypes of leukemias such as PRECURSOR CELL LYMPHOBLASTIC LEUKEMIA-LYMPHOMA; LEUKEMIA, MYELOGENOUS, CHRONIC, BCR-ABL POSITIVE; and NEUTROPHILIC LEUKEMIA, CHRONIC.
Descriptor ID |
D016044
|
MeSH Number(s) |
D08.811.913.696.620.682.725.500.500 D12.776.602.500.500.100 D12.776.624.664.500.100 D12.776.624.664.700.171.500
|
Concept/Terms |
Fusion Proteins, bcr-abl- Fusion Proteins, bcr-abl
- Fusion Proteins, bcr abl
- bcr-abl Fusion Proteins
- bcr abl Fusion Proteins
- Bcr-Abl Tyrosine Kinase
- Bcr Abl Tyrosine Kinase
- Kinase, Bcr-Abl Tyrosine
- Tyrosine Kinase, Bcr-Abl
|
Below are MeSH descriptors whose meaning is more general than "Fusion Proteins, bcr-abl".
Below are MeSH descriptors whose meaning is more specific than "Fusion Proteins, bcr-abl".
This graph shows the total number of publications written about "Fusion Proteins, bcr-abl" by people in this website by year, and whether "Fusion Proteins, bcr-abl" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
Year | Major Topic | Minor Topic | Total |
---|
1994 | 2 | 1 | 3 |
1995 | 2 | 1 | 3 |
1996 | 2 | 3 | 5 |
1997 | 2 | 0 | 2 |
1998 | 5 | 5 | 10 |
1999 | 7 | 1 | 8 |
2000 | 2 | 4 | 6 |
2001 | 8 | 1 | 9 |
2002 | 5 | 7 | 12 |
2003 | 8 | 7 | 15 |
2004 | 9 | 3 | 12 |
2005 | 6 | 6 | 12 |
2006 | 17 | 8 | 25 |
2007 | 13 | 24 | 37 |
2008 | 12 | 17 | 29 |
2009 | 16 | 14 | 30 |
2010 | 12 | 10 | 22 |
2011 | 12 | 9 | 21 |
2012 | 14 | 7 | 21 |
2013 | 11 | 10 | 21 |
2014 | 9 | 6 | 15 |
2015 | 6 | 5 | 11 |
2016 | 6 | 8 | 14 |
2017 | 10 | 7 | 17 |
2018 | 7 | 4 | 11 |
2019 | 4 | 8 | 12 |
2020 | 6 | 6 | 12 |
2021 | 2 | 2 | 4 |
2022 | 1 | 7 | 8 |
2023 | 1 | 12 | 13 |
2024 | 0 | 2 | 2 |
To return to the timeline,
click here.
Below are the most recent publications written about "Fusion Proteins, bcr-abl" by people in Profiles.
-
Navigating the Management of Chronic Phase CML in the Era of Generic BCR::ABL1 Tyrosine Kinase Inhibitors. J Natl Compr Canc Netw. 2024 02; 22(1).
-
Dose modification dynamics of ponatinib in patients with chronic-phase chronic myeloid leukemia (CP-CML) from the PACE and OPTIC trials. Leukemia. 2024 Mar; 38(3):475-481.
-
Aleukemic Chronic Myeloid Leukemia Without Neutrophilia and Thrombocytosis: A Report From the BCR::ABL1 Pathology Group. Mod Pathol. 2024 Feb; 37(2):100406.
-
An Update on the Management of Advanced Phase Chronic Myeloid Leukemia. Curr Hematol Malig Rep. 2023 Dec; 18(6):234-242.
-
Characteristics and outcomes of patients with chronic myeloid leukemia and T315I mutation treated in the pre- and post-ponatinib era. Am J Hematol. 2023 10; 98(10):1619-1626.
-
Classification of accelerated phase chronic myeloid leukemia in the era of the BCR::ABL1 tyrosine kinase inhibitors: A work in progress. Am J Hematol. 2023 09; 98(9):1350-1353.
-
Molecular response in newly diagnosed chronic-phase chronic myeloid leukemia: prediction modeling and pathway analysis. Haematologica. 2023 06 01; 108(6):1567-1578.
-
Low-Dose Dasatinib (50 mg Daily) Frontline Therapy in Newly Diagnosed Chronic Phase Chronic Myeloid Leukemia: 5-Year Follow-Up Results. Clin Lymphoma Myeloma Leuk. 2023 10; 23(10):742-748.
-
Ultrasensitive NGS MRD assessment in Ph+?ALL: Prognostic impact and correlation with RT-PCR for BCR::ABL1. Am J Hematol. 2023 08; 98(8):1196-1203.
-
Management of chronic myeloid leukemia in 2023 - common ground and common sense. Blood Cancer J. 2023 04 24; 13(1):58.